Shaily Engineering Plastics Ltd. – Investor Presentation Summary

Key Operational Highlights

  • Two new contracts signed for IP led platforms in healthcare segment
  • Launched Shaily AI TobyTM Reusable two-step reusable auto-injector pen for GLP-1 therapies
  • 25 Mn pens capacity addition with automation machines under commissioning and validation
  • Business confirmation received for new product from existing home furnishing customer
  • Business confirmation received for increased volumes for existing product from home furnishing customer
  • Business confirmation received for 7 new products on Power Tools
  • Business confirmation received for new knobs from an Appliance customer

Key drivers of operational performance: Improved traction in healthcare segment, new product launches, capacity expansion, and automation initiatives

Segment-wise Performance

Healthcare segment showed improved traction and has been the key driver for overall business growth

Consumer and Industrial segments received new business confirmations from existing customers

Explanation of significant changes in segment performance: Healthcare segment growth driven by Semaglutide pens supply and new auto-injector platform launch

Financial Highlights

Revenue: Rs. 319.5 Cr (Q2 FY27), Rs. 600.2 Cr (H1 FY27)

EBITDA: Rs. 101.8 Cr (Q2 FY27), Rs. 185.1 Cr (H1 FY27)

PAT: Rs. 61.3 Cr (Q2 FY27), Rs. 109.3 Cr (H1 FY27)

EPS: Not Specified

Margins: EBITDA Margin 31.9% (Q2 FY27), 30.8% (H1 FY27); PAT Margin 19.2% (Q2 FY27), 18.2% (H1 FY27)

YoY comparison: Revenue up 24% YoY (Q2), 19% YoY (H1); EBITDA up 25% YoY (Q2), 22% YoY (H1); PAT up 20% YoY (Q2), 18% YoY (H1)

Drivers of financial performance: Revenue growth, operational efficiencies, sustainable healthy operating margins

Comparison to market estimates: Not Specified

Key Risks: Not Specified

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Not Specified

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Other Equity Rs. 825.5 Cr (Sep-26)

Current Assets/Liabilities: Current Assets Rs. 546.6 Cr, Current Liabilities Rs. 398.8 Cr (Sep-26)

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Strengthening leverage and debt coverage indicators, growth in total operating income

Capex & Cash Flow Health

Capital Expenditure: Expected investment of AED 130-150 million (~Rs.350 Cr) for Abu Dhabi facility

Free Cash Flow: Not Specified

Operating Cash Flow: Net Cash from Operating Activities Rs. 110.5 Cr (H1 FY27)

Net Debt Movement: Long-term borrowings reduced to Rs. 21.9 Cr from Rs. 27.3 Cr (Mar-26 to Sep-26)

Investment Rationale: Strategic expansion to support global GLP-1 opportunity, capacity addition for medical devices

Strategic & R&D Initiatives

Investments in Innovation: Setting up facility in Abu Dhabi for manufacturing Medical Devices, automation machines for pen production

Expected impact on growth: Abu Dhabi facility expected to add capacity of 75 Mn pens annually

Strategic Rationale: Support global GLP-1 opportunity, expand medical device manufacturing capabilities

Industry Trends & Business Environment

Macro/Industry Trends: Global GLP-1 therapy market opportunity

Impact on Company: Strategic expansion to capture GLP-1 opportunity, new product development for sustainable medical devices

Management Commentary & Growth Outlook

Strategic Outlook: Not Specified

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Not Specified

Other Updates

Rating Upgrade by CARE Ratings: Short Term Bank Facilities of Rs.35 Cr upgraded to CARE A1+ from CARE A1

Long Term Bank Facilities: Rs. 239.24 Cr reaffirmed at CARE A+ with Stable Outlook